AlphaGalileo is a service for the media.
Journalists should register for free access to embargoed
news and press office contact information.
Please register view details
Please register to view contact details
Please log in or register to view articles older than 3 months
This item is under embargo and is only visible to journalists
Bookmark this item in My Area
This item is bookmarked
Add comments to this news release
A new review highlights the potential of nicotinamide (Vitamin B3) for preventing melanoma in high-risk individuals.Nicotinamide can help reduce or reverse DNA damage, inflammation, and immunosuppression caused by ultraviolet radiation.The cost of nicotinatimide is approximately $10 per month if taken at 1g per day as recommended. Randomized placebo controlled trials are now warranted to determine its efficacy and safety for melanoma prevention.“Nicotinamide has been show in a clinical trial—called ONTRAC—to reduce the incidence of non-melanoma skin cancer in high-risk individuals and it would be worthwhile to determine whether it would also be useful for high-risk melanoma patients,” said Dr. Gary Halliday, senior author of the Photodermatology, Photoimmunology & Photomedicine review.
Rashi Minocha, Diona L. Damian and Gary M. Halliday. Melanoma and nonmelanoma skin cancer chemoprevention: A role for nicotinamide? Photodermatology, Photoimmunology & Photomedicine. DOI: 10.1111/phpp.12328.
This item has been withdrawn. Registered users can contact the publishing organisation for further details by logging in